FBTCX Performance — Fidelity Advisor Biotechnology Fund, Class C
Data updated: 2026-10-13
FBTCX returned +20.13% year to date and +61.05% over one year to Jul 2026. Over one year the fund beat its Health Care Equity category average: $100 grew to $161, against $137 for the category. Volatility over the past 12 months was 21.03% a year. In the 12 months to Jul 2026 the fund lost a net $22.5M, and assets reached $2.20B.
FBTCX Growth of $100
What $100 invested in Fidelity Advisor Biotechnology Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | FBTCX | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $161 | $137 |
| 3 years (Aug 2023 – Jul 2026) | $157 | $137 |
| 5 years (Aug 2021 – Jul 2026) | $114 | $121 |
| Since data start (Aug 2019 – Jul 2026) | $132 | $183 |
FBTCX Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +20.13% |
| 1 year | +61.05% |
3- and 5-year figures withheld: disagrees with sibling classes.
FBTCX Annual Returns
Calendar-year total returns of Fidelity Advisor Biotechnology Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +20.13% |
| 2025 | +35.77% |
| 2024 | −7.01% |
| 2023 | −2.35% |
| 2022 | −18.81% |
| 2021 | −14.88% |
| 2020 | +16.62% |
| 2019 (Aug–Dec) | +10.67% |
FBTCX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +1.4% | +2.1% | −1.4% | +2.0% | +0.5% | +15.8% | −0.8% | — | — | — | — | — |
| 2025 | −0.1% | −1.7% | −5.2% | +0.5% | −3.3% | +3.5% | +8.0% | +5.8% | +10.8% | +8.5% | +10.5% | −4.7% |
| 2024 | +3.1% | +5.5% | +0.9% | −9.9% | +0.6% | +3.4% | +6.8% | +2.0% | −0.5% | −0.6% | −7.1% | −9.6% |
| 2023 | +0.1% | −4.6% | −3.4% | +2.2% | −0.7% | −0.6% | +1.2% | −4.0% | −5.1% | −6.7% | +3.1% | +18.4% |
| 2022 | −13.7% | −0.8% | +3.8% | −14.1% | −7.2% | +4.5% | +1.6% | +7.4% | −3.0% | +4.4% | +0.6% | −1.4% |
| 2021 | −0.5% | −0.5% | −5.7% | +0.3% | −5.9% | +4.5% | −2.9% | +7.6% | −6.1% | +0.2% | −7.3% | +1.4% |
| 2020 | −6.3% | −0.7% | −7.9% | +13.7% | +10.0% | +1.2% | −4.3% | +0.7% | +0.1% | −2.9% | +11.4% | +3.1% |
| 2019 | — | — | — | — | — | — | — | −2.8% | −4.1% | +5.5% | +10.4% | +1.9% |
FBTCX Risk
Risk measures from monthly returns over Aug 2025 – Jul 2026.
- 1-year volatility (annualised): 21.03%
- Best month: +15.75% (Jun 2026)
- Worst month: −4.72% (Dec 2025)
FBTCX Fund Flows
Monthly money in and out of Fidelity Advisor Biotechnology Fund, from SEC Form N-PORT.
- 12-month net flow: −$22.5M
- 12-month gross sales (incl. reinvestments): $320.8M
- Sales ÷ redemptions: 0.93×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $42.1M | $28.9M | $13.2M |
| Jun 2026 | $27.9M | $27.8M | $95K |
| May 2026 | $16.4M | $28.0M | −$11.6M |
| Apr 2026 | $18.8M | $25.9M | −$7.0M |
| Mar 2026 | $19.0M | $24.8M | −$5.8M |
| Feb 2026 | $25.7M | $29.6M | −$4.0M |
| Jan 2026 | $24.4M | $27.8M | −$3.4M |
| Dec 2025 | $53.3M | $27.5M | $25.8M |
| Nov 2025 | $33.2M | $26.7M | $6.5M |
| Oct 2025 | $25.9M | $31.1M | −$5.2M |
| Sep 2025 | $16.4M | $28.1M | −$11.6M |
| Aug 2025 | $17.6M | $37.0M | −$19.4M |
FBTCX Assets Under Management
Net assets of Fidelity Advisor Biotechnology Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $2.20B |
| 2026-04-30 | $1.90B |
| 2026-01-31 | $1.87B |
| 2025-10-31 | $1.74B |
| 2025-07-31 | $1.40B |
| 2025-04-30 | $1.37B |
| 2025-01-31 | $1.54B |
| 2024-10-31 | $1.88B |
| 2024-07-31 | $1.81B |
| 2024-04-30 | $1.63B |
| 2024-01-31 | $1.68B |
| 2023-10-31 | $1.36B |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.